Citation Impact
Citing Papers
Cancer treatment and survivorship statistics, 2022
2022 Standout
V804M RET mutation and familial medullary thyroid carcinoma: Report of a large family with expression of the disease only in the homozygous gene carriers
2002
Atypical MEN Type 2B Associated with Two Germline RET Mutations on the Same Allele Not Involving Codon 918
2002
Genotype-phenotype correlations in Hungarian patients with hereditary medullary thyroid cancer
2006
Peak Incidence of Pheochromocytoma and Primary Hyperparathyroidism in Multiple Endocrine Neoplasia 2: Need for Age-Adjusted Biochemical Screening
2013
Thyroid cancer
2016 Standout
Frequent association between MEN 2A and cutaneous lichen amyloidosis
2003
RET oncogene mutations in 75 cases of familial medullary thyroid carcinoma in Japan
2004
Novel point mutation in exon 10 of theRET proto-oncogene in a family with medullary thyroid carcinoma
1998
Two Germline Missense Mutations at Codons 804 and 806 of the RET Proto‐oncogene in the Same Allele in a Patient with Multiple Endocrine Neoplasia Type 2B without Codon 918 Mutation
1999
The Genetic Basis of Pheochromocytoma
2003
Type I interferons in infectious disease
2015 Standout
A Two-Hit Model for Development of Multiple Endocrine Neoplasia Type 2B by RET Mutations
2000
Presentation of a kindred with familial medullary thyroid carcinoma and Cys611Phe mutation of the RET proto-oncogene demonstrating low grade malignancy
2001
Occurrence of the Cys611Tyr mutation and a novel Arg886Trp substitution in the RET proto‐oncogene in multiple endocrine neoplasia type 2 families and sporadic medullary thyroid carcinoma cases originating from the central region of Portugal
2006
Characterization of the largest kindred with MEN2A due to a Cys609Ser RET mutation
2009
Comparison of flutamide and spironolactone in the treatment of hirsutism: a randomized controlled trial
1994
Somatic VHLgene alterations in MEN2-associated medullary thyroid carcinoma
2006
Germline Homozygous Mutations at Codon 804 in theRETProtooncogene in Medullary Thyroid Carcinoma/Multiple Endocrine Neoplasia Type 2A Patients
2005
2007 Guidelines for the Management of Arterial Hypertension
2007 Standout
Advances in the management of hereditary medullary thyroid cancer
2004
Polycystic Ovary Syndrome
1995 Standout
When should thyroidectomy be performed in familial medullary thyroid carcinoma gene carriers with non-cysteine RET mutations?
2003
Novel germline mutation in the transmembrane region of RET gene close to Cys634Ser mutation associated with MEN 2A syndrome
2004
RET proto-oncogene mutations affecting codon 790/791: A mild form of multiple endocrine neoplasia type 2A syndrome?
2002
Treatment of medullary thyroid carcinoma: an update.
2001
A Novel Point Mutation of theRETProtooncogene Involving the Second Intracellular Tyrosine Kinase Domain in a Family with Medullary Thyroid Carcinoma
2004
The Clinical Spectrum of Multiple Endocrine Neoplasia Type 2a Caused by the Rare IntracellularRETMutation S891A
2010
Treatment of hirsutism with the pure antiandrogen flutamide
1990
Molecular genetic diagnostic program of multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma syndromes in Hungary
2001
Polycystic ovary syndrome
2016 Standout
Treatment of advanced medullary thyroid carcinoma with a combination of recombinant interferon α-2b and octreotide
1996
Multiple endocrine neoplasia type 2 andRET: from neoplasia to neurogenesis
2000
Early Malignant Progression of Hereditary Medullary Thyroid Cancer
2003
Multiple endocrine neoplasia type 2 and the RET protooncogene: From bedside to bench to bedside
2005
Prophylactic thyroidectomy in multiple endocrine neoplasia: the impact of molecular mechanisms of RET proto-oncogene
2003
Update on the MEN 2A c804 RET mutation: Is prophylactic thyroidectomy indicated?
2000
The RET Mutation E768D Confers a Late-onset Familial Medullary Thyroid Carcinoma – Only Phenotype with Incomplete Penetrance: Implications for Screening and Management of Carrier Status
2006
Asymptomatic bilateral adrenal pheochromocytoma in a patient with a germline V804M mutation in the RET proto‐oncogene
2007
Familial Medullary Thyroid Carcinoma with Noncysteine RET Mutations: Phenotype-Genotype Relationship in a Large Series of Patients
2001
Inhibition of chlamydia trachomatis growth by human interferon-.ALPHA.: mechanisms and synergistic effect with interferon-.GAMMA. and tumor necrosis factor-.ALPHA.
2005
Mutation analysis of the RET proto-oncogene and early thyroidectomy: results of a Portuguese cancer centre
2006
Exon 5 of the RET proto-oncogene: A newly detected risk exon for familial medullary thyroid carcinoma, a novel germ-line mutation Gly321Arg
2005
Pheochromocytoma and Medullary Thyroid Carcinoma: A New Genotype-Phenotype Correlation of theRETProtooncogene 891 Germline Mutation
2004
Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma
2015 Standout
Medullary Thyroid Cancer: Management Guidelines of the American Thyroid Association
2009 Standout
RET Proto-Oncogene in Sardinia: V804M Is the Most Frequent Mutation and May Be Associated with FMTC/MEN-2A Phenotype
2007
2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum
2017 Standout
Screening of six risk exons of the RET proto-oncogene in families with medullary thyroid carcinoma in the Czech Republic
2004
RET as a Diagnostic and Therapeutic Target in Sporadic and Hereditary Endocrine Tumors
2006
American Association Of Clinical Endocrinologists, Associazione Medici Endocrinologi, And European Thyroid Association Medical Guidelines For Clinical Practice For The Diagnosis And Management Of Thyroid Nodules
2010 Standout
RET Is Constitutively Activated by Novel Tandem Mutations that Alter the Active Site Resulting in Multiple Endocrine Neoplasia Type 2B
2006
Familial Medullary Thyroid Carcinoma: Clinical Variability and Low Aggressiveness Associated withRETMutation at Codon 804
2002
High prevalence of the C634Y mutation in the RET proto-oncogene in MEN 2A families in Spain
1999
Comparative Effects of Cyproterone Acetate or a Long-Acting Gonadotropin-Releasing Hormone Agonist in Polycystic Ovarian Disease
1986
A Novel 9-Base Pair Duplication in RET Exon 8 in Familial Medullary Thyroid Carcinoma1
1999
Estimation of Risk of Inherited Medullary Thyroid Carcinoma in Apparent Sporadic Patients
2001
[Medullary thyroid carcinoma: the comparison of the hereditary and sporadic types of cancer].
2007
Review of Multiple Endocrine Neoplasia Type 2A in Children: Therapeutic Results of Early Thyroidectomy and Prognostic Value of Codon Analysis
2003
Cancer treatment and survivorship statistics, 2019
2019 Standout
American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi Medical Guidelines for Clinical Practice for the Diagnosis and Management of Thyroid Nodules - 2016 Update Appendix
2016 Standout
Interventions for hirsutism (excluding laser and photoepilation therapy alone)
2015
Guidelines for the management of thyroid cancer
2014 Standout
RET Proto-Oncogene in the Development of Human Cancer
1999
Thyroid carcinoma
2003 Standout
Works of A. Libroia being referenced
Seventeen-year-long follow-up of a family affected by type 2A Multiple Endocrine Neoplasia (MEN 2A)
1998
A GTG to ATG novel point mutation at codon 804 in exon 14 of the RET proto-oncogene in two families affected by familial medullary thyroid carcinoma
1998
A Novel Point Mutation in the Intracellular Domain of theretProtooncogene in a Family with Medullary Thyroid Carcinoma1
1997
α-Interferon Induces Depletion of Intracellular Iron Content and Up Regulation of Functional Transferrin Receptors on Human Epidermoid Cancer kb Cells
1994
Loss of Heterozygosity at theRETProtooncogene Locus in a Case of Multiple Endocrine Neoplasia Type 2A1
2001
Use of somatostatin analog SMS 201-995 in medullary thyroid carcinoma.
1989
Treatment of hirsutism and acne in women with two combinations of cyproterone acetate and ethinylestradiol.
1976
The role of radiopharmaceuticals MIBG and (V) DMSA in the diagnosis of medullary thyroid carcinoma.
1989